| Literature DB >> 34398999 |
Peina Shi1,2, Haojun Song1, Xiaoyun Ding1.
Abstract
BACKGROUND: Circular RNAs (circRNAs) are a novel family of endogenous RNAs. Recent studies have demonstrated that circRNAs are potential novel biomarkers for diagnosing cancers. However, little is known about the role of circRNAs in gastric cancer (GC). This study aimed to identify the relationship between GC and a new circRNA named hsa_circ_001888.Entities:
Keywords: biomarker; circular RNA; diagnosis; gastric cancer; hsa_circ_001888
Mesh:
Substances:
Year: 2021 PMID: 34398999 PMCID: PMC8418507 DOI: 10.1002/jcla.23953
Source DB: PubMed Journal: J Clin Lab Anal ISSN: 0887-8013 Impact factor: 2.352
FIGURE 1The genomic loci of the MFNG gene and hsa_circ_001888
FIGURE 2The relative expression of hsa_circ_001888 in gastric cancer cell lines. Hsa_circ_001888 expression levels in two human gastric cancer lines (AGS and MKN‐45) and normal gastric mucosa epithelial cell line (GES‐1) were determined by qRT‐PCR. Data are expressed as mean ± SD of three independent experiments. ** means p < 0.01, *** means p < 0.001
FIGURE 3The expression levels of hsa_circ_001888 in gastric cancer tissues and adjacent normal tissues. Hsa_circ_001888 and GAPDH expression levels were detected by qRT‐PCR. The ΔCq method was used to analyze the relative expression of hsa_circ_001888. Data are expressed as mean ± SD of three independent experiments. n = 114, *** means p < 0.001
FIGURE 4The expression levels of hsa_circ_001888 in gastric cancer plasma samples and healthy controls. Hsa_circ_001888 and GAPDH expression levels were detected by qRT‐PCR. Data are expressed as mean ± SD of three independent experiments. n = 48, *** means p < 0.001)
The relationship of hsa_circ_001888 expression levels (ΔCq) in gastric cancer tissues with clinicopathological factors of patients with gastric cancer
| Factors | No. of patients (%) | Mean ± SD | |
|---|---|---|---|
| Age (y) | |||
| <60 | 27 (23.68) | 7.86 ± 2.89 | 0.072 |
| ≥60 | 87 (76.32) | 8.97 ± 2.01 | |
| Gender | |||
| Male | 82 (71.93) | 8.76 ± 2.43 | 0.687 |
| Female | 32 (28.07) | 8.57 ± 1.91 | |
| Diameter (cm) | |||
| ≥5 | 47 (41.23) | 8.41 ± 2.18 | 0.250 |
| <5 | 67 (58.77) | 8.91 ± 2.35 | |
| Differentiation | |||
| Well + moderate | 20 (0.18) | 9.72 ± 1.59 |
|
| Poor + undifferentiation | 94 (0.82) | 8.49 ± 2.36 | |
| TNM Stage | |||
| 0&Ⅰ&Ⅱ | 21 (0.18) | 9.04 ± 2.46 | 0.463 |
| Ⅲ&Ⅳ | 93 (0.82) | 8.63 ± 2.25 | |
| Invasion | |||
| Tis&T1 | 6 (0.06) | 8.03 ± 2.11 | 0.458 |
| T2&T3&T4 | 108 (0.94) | 8.75 ± 2.30 | |
| Lymphatic metastasis | |||
| N0 | 19 (0.17) | 9.08 ± 2.46 | 0.434 |
| N1&N2&N3 | 95 (0.83) | 8.63 ± 2.26 | |
| Distal metastasis | |||
| M0 | 105 (0.92) | 8.68 ± 2.28 | 0.721 |
| M1 | 9 (0.08) | 8.97 ± 2.47 | |
| Venous invasion | |||
| Absent | 38 (0.33) | 8.91 ± 2.15 | 0.512 |
| Present | 76 (0.67) | 8.61 ± 2.36 | |
| Perineural invasion | |||
| Absent | 49 (0.43) | 8.92 ± 2.36 | 0.394 |
| Present | 65 (0.57) | 8.55 ± 2.23 | |
| CEA | |||
| Positive | 31 (0.27) | 8.52 ± 2.08 | 0.600 |
| Negative | 83 (0.73) | 8.78 ± 2.37 | |
| CA19‐9 | |||
| Positive | 24 (0.21) | 8.79 ± 1.39 | 0.797 |
| Negative | 90 (0.79) | 8.69 ± 2.48 | |
Bold indicates statistical significant value (p < 0.05).
The relationship of hsa_circ_001888 expression levels (ΔCq) in plasma from patients with gastric cancer and clinicopathological factors of patients with gastric cancer
| Factors | No. of patients (%) | Mean ± SD | |
|---|---|---|---|
| Age (y) | |||
| <60 | 14 (0.29) | 4.32 ± 2.26 | 0.424 |
| ≥60 | 34 (0.71) | 3.77 ± 2.11 | |
| Gender | |||
| Male | 26 (0.54) | 3.91 ± 2.49 | 0.952 |
| Female | 22 (0.46) | 3.95 ± 1.71 | |
| Diameter (cm) | |||
| ≥5 | 21 (0.43) | 4.33 ± 2.06 | 0.259 |
| <5 | 27 (0.56) | 3.62 ± 2.19 | |
| Differentiation | |||
| Well + moderate | 15 (0.31) | 4.47 ± 2.02 | 0.241 |
| Poor + undifferentiation | 33 (0.69) | 3.68 ± 2.18 | |
| TNM Stage | |||
| 0&Ⅰ&Ⅱ | 23 (0.48) | 3.53 ± 2.10 | 0.213 |
| Ⅲ&Ⅳ | 25 (0.52) | 4.30 ± 2.16 | |
| Invasion | |||
| Tis&T1 | 10 (0.21) | 3.35 ± 2.26 | 0.339 |
| T2&T3&T4 | 38 (0.79) | 4.0 ± 2.12 | |
| Lymphatic metastasis | |||
| N0 | 19 (0.40) | 3.68 ± 2.17 | 0.514 |
| N1&N2&N3 | 29 (0.60) | 4.10 ± 2.15 | |
| Distal metastasis | |||
| M0 | 47 (0.98) | 3.85 ± 2.09 | 0.065 |
| M1 | 1 (0.02) | 7.83 | |
| Venous invasion | |||
| Absent | 23 (0.48) | 3.62 ± 1.96 | 0.346 |
| Present | 25 (0.52) | 4.21 ± 2.30 | |
| Perineural invasion | |||
| Absent | 29 (0.60) | 3.75 ± 2.11 | 0.479 |
| Present | 19 (0.40) | 4.20 ± 2.22 | |
| CEA | |||
| Positive | 39 (0.81) | 3.38 ± 1.89 |
|
| Negative | 9 (0.19) | 6.30 ± 1.50 | |
| CA19‐9 | |||
| Positive | 43 (0.90) | 3.71 ± 2.08 |
|
| Negative | 5 (0.10) | 5.82 ± 1.82 | |
Bold indicates statistical significant value (p < 0.05).
FIGURE 5ROC curve of hsa_circ_001888